Literature DB >> 3838113

Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia.

S H Abman, R R Wolfe, F J Accurso, B L Koops, C M Bowman, J W Wiggins.   

Abstract

The cardiac catheterization data of six infants with bronchopulmonary dysplasia (BPD) were reviewed to examine the responsiveness of their pulmonary vascular beds to changes in oxygen tension. The infants were studied because of slow recovery from their oxygen requirements and clinical evidence of persistent pulmonary hypertension. All were receiving home oxygen therapy and had abnormal chest radiographs and right ventricular hypertrophy by ECG at the time of catheterization (mean age, 25 months). All infants had mean pulmonary artery pressure greater than 25 mm Hg in room air, with a mean of 48 mm Hg. All decreased mean pulmonary artery pressure by at least 10 mm Hg when placed in high levels of inspired oxygen (FiO2 greater than 80), with a mean pulmonary artery pressure of 25 mm Hg. This represented a significant decrease in mean pulmonary artery pressure from room air pressures (P less than .005). Mean pulmonary artery pressure was also measured in three infants who were breathing supplemental oxygen by nasal cannula at flow rates similar to levels used for outpatient therapy. Most of the reduction in mean pulmonary artery pressure that occurred at high FiO2 occurred at these lower flow rates of supplemental oxygen. It is concluded that infants with bronchopulmonary dysplasia who have pulmonary hypertension generally have reactive pulmonary vascular beds, responsive to supplemental oxygen. Continuous oxygen therapy by nasal cannula may be useful in the treatment of pulmonary hypertension associated with bronchopulmonary dysplasia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838113

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  31 in total

1.  Changes in pulmonary arterial pressure in preterm infants with chronic lung disease.

Authors:  N V Subhedar; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

Review 2.  A risk-benefit assessment of drugs used for neonatal chronic lung disease.

Authors:  D G Sweet; H L Halliday
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 3.  Monitoring cardiovascular function in infants with chronic lung disease of prematurity.

Authors:  S H Abman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-07       Impact factor: 5.747

Review 4.  Home oxygen for children: who, how and when?

Authors:  I M Balfour-Lynn; R A Primhak; B N J Shaw
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

5.  Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs.

Authors:  Richard D Bland; Kurt H Albertine; David P Carlton; Amy J MacRitchie
Journal:  Am J Respir Crit Care Med       Date:  2005-06-23       Impact factor: 21.405

Review 6.  Current perspectives on the prevention and management of chronic lung disease in preterm infants.

Authors:  Prakesh S Shah
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 7.  Progress in understanding the pathogenesis of BPD using the baboon and sheep models.

Authors:  Kurt H Albertine
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

Review 8.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  Sara K Berkelhamer; Karen K Mestan; Robin H Steinhorn
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

9.  Pulmonary hypertension in extremely low birth weight infants: characteristics and outcomes.

Authors:  Wambui Waruingi; Maroun Jean Mhanna
Journal:  World J Pediatr       Date:  2014-01-25       Impact factor: 2.764

10.  Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia.

Authors:  Hyo Soon An; Eun Jung Bae; Gi Beom Kim; Bo Sang Kwon; Jae Suk Beak; Ee Kyung Kim; Han Suk Kim; Jung-Hwan Choi; Chung Il Noh; Yong Soo Yun
Journal:  Korean Circ J       Date:  2010-03-24       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.